Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies

Abstract Background Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. Methods This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naïve patients. The patients were treated and monitored for 12 months. Each patient was administered with an aflibercept (2.0 mg) injection every month for the first 3 months (the loading phase), and thereafter, once every 2 months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12 months. Results After 12 months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (p< 0.001). Additionally, ten patients (40%) showed complete polyp regression. The treatment-naïve patients showed a statistically significant improvement in BCVA from 66.58 letters at baseline to 76.36 letters at 12 months, and a significant decrease in CSMT, from 462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically significant. Conclusions The fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-naïve patients than in pre-treated patients. Trial registration Clinical Research Information Service (CRiS), Republic of Korea. Identifer: KCT0005798, Registered: Jan 20, 2021. Retrospectively registered, URL: https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18546

Download Full-text

Depression in Men and Women One Year Following Traumatic Brain Injury (TBI): A TBI Model Systems Study

Frontiers in Psychology ◽

10.3389/fpsyg.2017.00634 ◽

2017 ◽

Vol 8 ◽

Cited By ~ 17

Author(s):

Sarah Lavoie ◽

Samantha Sechrist ◽

Nhung Quach ◽

Reza Ehsanian ◽

Thao Duong ◽

...

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Model Systems ◽

Men And Women ◽

One Year

Download Full-text

One-year psoas training can prevent lumbar bone loss in postmenopausal women: A randomized controlled trial

Calcified Tissue International ◽

10.1007/bf01351834 ◽

1993 ◽

Vol 53 (5) ◽

pp. 307-311 ◽

Cited By ~ 52

Author(s):

M. Revel ◽

M. A. Mayoux-Benhamou ◽

J. P. Rabourdin ◽

F. Bagheri ◽

C. Roux

Keyword(s):

Randomized Controlled Trial ◽

Bone Loss ◽

Postmenopausal Women ◽

Controlled Trial ◽

Randomized Controlled ◽

One Year

Download Full-text

Prevention of early postmenopausal bone loss by risedronate: One year follow-up data

Bone ◽

10.1016/8756-3282(96)87981-6 ◽

1995 ◽

Vol 17 (6) ◽

pp. 607 ◽

Cited By ~ 2

Author(s):

L. Mortensen ◽

P. Bekker ◽

J. DiGennaro ◽

D. Axelrod ◽

P. Charles ◽

...

Keyword(s):

Bone Loss ◽

Postmenopausal Bone Loss ◽

One Year ◽

Early Postmenopausal Bone Loss

Download Full-text

P2X7 receptor/NLRP3 inflammasome complex and a-synuclein/parkin balance in neo-diagnosed, treatment-naïve Parkinson disease: a prospective study

10.21203/rs.3.rs-38800/v1 ◽

2020 ◽

Author(s):

Anna Solini ◽

Chiara Rossi ◽

Eleonora Santini ◽

Martina Giuntini ◽

Francesco Raggi ◽

...

Keyword(s):

Epigenetic Regulation ◽

Nlrp3 Inflammasome ◽

Transcriptional Control ◽

De Novo ◽

Mechanistic Explanation ◽

Intracellular Signalling ◽

Newly Diagnosed ◽

Treatment Naïve ◽

One Year ◽

A Prospective Study

Abstract Background Neuro, and likely systemic inflammation, with abnormal α-synuclein deposition, participate in the development of Parkinson’s disease (PD). The P2 × 7 receptor/NLRP3 inflammasome complex is upregulated in the brain of PD patients. Aim of this study was to explore whether the systemic activation of such complex might participate in the pathogenesis of PD. Methods Systemic expression and functional activity of the inflammasome were measured in 25 newly diagnosed PD patients and 25 controls at baseline and after twelve months of pharmacologic treatment, exploring the involved intracellular signalling and its epigenetic regulation. A putative mechanistic explanation of the results was validated in a murine model of neuroinflammation. Results De-novo PD patients were characterized by a systemic hyper-expression of the P2 × 7R/NLRP3 inflammasome platform, likely modulating circulating and lymphomonocyte α-synuclein, whose deposits represent the main pathogenetic factor of PD. A reduced JNK phosphorylation might be the involved intracellular signalling. miR-7 and miR-30, implied in the pathogenesis of PD and in the post-transcriptional control of α-synuclein and NLRP3 expression, were also increased in PD. After one year of usual anti-Parkinson treatments, such inflammatory platform was significantly reduced. In the substantia nigra of P2 × 7R KO mice, a neuroinflammatory stimulus induced a strong expression of parkin, a protective protein, suggesting that P2 × 7R activation might participate in the inflammatory damage occurring in specific brain areas also by inhibiting parkin expression. Conclusion Newly-diagnosed PD subjects display a systemic hyper-expression of the P2 × 7R/NLRP3 inflammasome platform that seems to modulate circulating and lymphomonocyte α-synuclein; a reduced JNK phosphorylation might be the intracellular signalling mediating this effect, undergoing an epigenetic regulation by miR-7 and miR-30. Trial registration ClinicalTrials.gov (NCT03918616).

Download Full-text

Observation of genotype C infected chronic hepatitis B patients in clinical practice

The Journal of Infection in Developing Countries ◽

10.3855/jidc.1480 ◽

2011 ◽

Vol 5 (12) ◽

pp. 882-889 ◽

Cited By ~ 2

Author(s):

Myo Nyein Aung ◽

Wattana Leowattana ◽

Noppadon Tangpukdee ◽

Chatporn Kittitrakul

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Clinical Information ◽

Hbv Dna ◽

Hbv Genotype ◽

Surrogate Outcome ◽

Treatment Naïve ◽

Genotype C ◽

One Year

Introduction: Hepatitis B virus (HBV) genotype C is prevalent in many areas of the world including Thailand and Southeast Asia. It is a strong risk for hepatocellular carcinoma (HCC) by evidence. We aimed to describe the baseline clinical information of treatment naïve genotype C infected chronic hepatitis B (CHB) patients and to describe the treatment response by surrogate outcome markers in genotype C infected CHB patients after one year of nucleos(t)ide analogues (NA) treatment Methodology: Thirty-four genotype C CHB patients were studied at the Hospital for Tropical Diseases, Bangkok, including 12 patients treated with lamivudine, 11 with telbivudine, 8 with adefovir, and 3 with entecavir. Serum HBV DNA levels, serum alanine amino transferase ( ALT ) levels, HBeAg status, and alpha-feto protein (AFP) levels were recorded at the start and after twelve months of ongoing treatment. HBV genotyping was performed by line-probe assay. Results: About half of the patients (58.8%) were HBeAg positive. Mean HBV viral load was 6.53 + 1.15 log10 copies per ml at baseline and reduced to 3.63 + 1.3 log10 copies per ml after one year of NA treatment. Serum HBV DNA levels became undetectable in 47.1 % of the patients and serum ALT was normalized in 23.5 % of the patients. Conclusion: Most of the genotype C patients were aged above 40 years. More than half of the genotype C infected patients did not achieve virological response and biochemical remission. Among the CHB patients, genotype C infected patients are a high priority group for intervention.

Download Full-text

The Effect of Tapered Abutments on Marginal Bone Level: A Retrospective Cohort Study

Journal of Clinical Medicine ◽

10.3390/jcm8091305 ◽

2019 ◽

Vol 8 (9) ◽

pp. 1305 ◽

Cited By ~ 3

Author(s):

Simone Marconcini ◽

Enrica Giammarinaro ◽

Ugo Covani ◽

Eitan Mijiritsky ◽

Xavier Vela ◽

...

Keyword(s):

Cohort Study ◽

Bone Loss ◽

Linear Measurement ◽

Bone Preservation ◽

Bone Level ◽

Marginal Bone Level ◽

Loading Methods ◽

One Year ◽

Average Bone

Background: Early peri-implant bone loss has been associated to long-term implant-prosthetic failure. Different technical, surgical, and prosthetic techniques have been introduced to enhance the clinical outcome of dental implants in terms of crestal bone preservation. The aim of the present cohort study was to observe the mean marginal bone level around two-part implants with gingivally tapered abutments one year after loading. Methods: Mean marginal bone levels and change were computed following radiological calibration and linear measurement on standardized radiographs. Results: Twenty patients who met the inclusion criterion of having at least one implant with the tapered prosthetic connection were included in the study. The cumulative implant success rate was 100%, the average bone loss was −0.18 ± 0.72 mm, with the final bone level sitting above the implant platform most of the time (+1.16 ± 0.91 mm). Conclusion: The results of this cohort study suggested that implants with tapered abutments perform successfully one year after loading and that they are associated with excellent marginal bone preservation, thus suggesting that implant-connection macro-geometry might have a crucial role in dictating peri-implant bone levels.

Download Full-text